← Back to patent-cliff list
CAS 16874-06-9
di-tert-butyl L-glutamateL-Glutamic acid di(tert-butyl) ester
Codes: PRAL-017, Lutetium (177Lu) vipivotide tetraxetan-002
Application context (from source-drug indications)
Peripheral T-cell lymphomaPralatrexateT-cell lymphomaPralatrexateSolid tumourPralatrexateHaematological malignancyPralatrexateB-cell lymphomaPralatrexateCutaneous T-cell lymphomaPralatrexateHormone-sensitive prostate cancerLutetium (177Lu) vipivotide tetraxetanCastration-resistant prostate cancerLutetium (177Lu) vipivotide tetraxetanProstate cancerLutetium (177Lu) vipivotide tetraxetanLiver cancerLutetium (177Lu) vipivotide tetraxetanHepatocellular carcinomaLutetium (177Lu) vipivotide tetraxetanRenal cell carcinomaLutetium (177Lu) vipivotide tetraxetan
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pralatrexate | Tier C — Watch / trade | - |
| Lutetium (177Lu) vipivotide tetraxetan | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid→methyl 4-formylbenzoate→methyl 5'-methyl-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylate→methyl 4-(6-oxohept-1-yn-4-yl)benzoate→dimethyl carbonate→methyl 4-(8-methoxy-6,8-dioxooct-1-yn-4-yl)benzoate→(E)-4-(7-(hydroxyimino)-6-oxohept-1-yn-4-yl)benzoic acid→pyrimidine-2,4,5,6-tetraamine hydrochloride→di-tert-butyl L-glutamate→di-tert-butyl (4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoyl)-L-glutamate
L-Glutamic acid di-tert-butyl ester hydrochloride→L-Glutamic acid di(tert-butyl) ester→Di-tert-butyl 2(S)-isocyanatopentanedioate→Di-tert-butyl N-[(trichloromethoxy)carbonyl]-L-glutamate→Resin bound H-Lys(Alloc)-OH→Resin bound (2S)-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)-6-([[(prop-2-en-1-yl)oxy]carbonyl]amino)hexanoic acid→Resin bound (2S)-6-amino-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid→Fmoc-2-Nal-OH→Resin bound 6-[[(2S)-2-amino-3-(naphthalen-2-yl)propanoyl]amino]-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid→Fmoc-tranexamic acid→Resin bound (2S)-6-[[(2S)-2-[[(1r,4S)-4-(aminomethyl)cyclohexane-1-carbonyl]amino]-3-(naphthalen-2-yl)propanoyl]amino]-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid→DOTA-Tris(t-Bu)ester→(3S,10S,14S)-3-[(Naphthalen-2-yl)methyl]-1,4,12-trioxo-1-[(1r,4S)-4-([2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetamido]methyl)cyclohexyl]-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid→N6-[(Allyloxy)carbonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysine→Resin bound N2-[[(9H-fluoren-9-yl)methoxy]carbonyl]-N6-[[(prop-2-en-1-yl)oxy]carbonyl]-L-lysine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.